Raynaud’s Disease Market to Register Incremental Growth During the Forecast Period (2022-2032), Asserts DelveInsight | Key Companies – Gesynta Pharma, United Therapeutics, Vicore Pharma, Arena Pharma

May 18 19:34 2023
Raynaud's Disease Market to Register Incremental Growth During the Forecast Period (2022-2032), Asserts DelveInsight | Key Companies - Gesynta Pharma, United Therapeutics, Vicore Pharma, Arena Pharma
The Raynaud’s Disease Market is set to register immense growth in the coming years owing to the rising prevalent population of patients in the 7MM, extensive research and development activities of pharmaceutical companies, and the launch of new therapies in the market.

Major pharma and biotech companies like Eicos Sciences, Gesynta Pharma AB, United Therapeutics, Camurus AB, and severl others are actively working towards the development of new treatment therapies for Raynaud’s Disease at the global level.

DelveInsight’s “Raynaud’s Disease Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Raynaud’s Disease market size, share, and trends in the seven major markets (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan).

The Raynaud’s Disease market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Raynaud’s Disease: An Overview

In response to cold temperatures, the body adapts by restricting blood flow to the skin. This is done as a thermoregulating mechanism to prevent further body heat loss and sustain the core body temperature. In the Raynaud phenomenon, blood-flow restriction occurs during cold temperatures and emotional stress. Specifically, in the Raynaud phenomenon, there is vasoconstriction of the digital arteries and cutaneous arterioles. 

Raynaud phenomenon is a transient and peripheral vasoconstrictive response to cold temperatures or emotional stress. Raynaud phenomenon can be categorized as either primary or secondary. Treatment of the Raynaud phenomenon aims at decreasing the frequency and severity of the attacks with the prevention of tissue ischemia.

Raynaud’s Disease Market Key Facts

  • The prevalence of secondary RP is related to the underlying disease. Progression to secondary RP occurs in 14–37 % of subjects with primary RP. Almost 99 % of patients who progress develop an autoimmune disease, most commonly systemic sclerosis (SSc). Risk factors for progression include positive ANA, elevated ESR, SSc-specific autoantibodies, and abnormal nail fold capillaroscopy.

  • Raynaud phenomena occur more frequently in women (about 20% to 30%), particularly in younger age populations (teens to 20s). The female-to-male ratio is 9 to 1. Low body weight is a risk factor for both sexes.

Raynaud's Disease Market

Raynaud’s Disease Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Raynaud’s Disease market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Raynaud’s Disease market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.

Raynaud’s Disease Epidemiology Assessment

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.

The Report Covers the Raynaud’s Disease Epidemiology Segmented by –

–   Diagnosed Prevalence Pool of Raynaud’s Disease (2019–2032)

–   Type-specific Pool of Raynaud’s Disease (2019–2032)

–   Gender-specific Pool of Raynaud’s Disease (2019–2032)

Learn More About the Evolving Epidemiology Trends @ Raynaud’s Disease Epidemiology Analysis

Raynaud’s Disease Drugs Uptake and Pipeline Development Activities

The drugs’ uptake section focuses on the rate of uptake of the potential drugs recently launched in the Raynaud’s Disease market or expected to get launched during the study period. The analysis covers the Raynaud’s Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers Raynaud’s Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About the Pipeline Development Activities in the Raynaud’s Disease Therapeutics Market @


Raynaud’s Disease Therapeutics Analysis

Several major pharma and biotech companies are developing therapies for Raynaud’s Disease. Currently, Gesynta Pharma is leading the therapeutics market with its Raynaud’s Disease drug candidates in the most advanced stage of clinical development.

Some of the Leading Companies in the Raynaud’s Disease Therapeutics Market Include:

  • –   Gesynta Pharma

  • –   United Therapeutics

  • –   Vicore Pharma

  • –   Arena Pharmaceuticals

And many others

Raynaud’s Disease Therapies Covered in the Report Include:

  • –   GS 248: Gesynta Pharma

  • –   Treprostinil: United Therapeutics

  • –   CiVi 030: Eicos Sciences

And many more

Get a more detailed analysis of Raynaud’s Disease Emerging Therapies and Key Companies @ 


Table of Content (TOC)

1. Key Insights

2. Executive Summary

3. Raynaud’s Disease Competitive Intelligence Analysis

4. Raynaud’s Disease Market Overview at a Glance

5. Disease Background and Overview

6. Raynaud’s Disease Patient Journey

7. Raynaud’s Disease Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Raynaud’s Disease Treatment Algorithm, Current Treatment, and Medical Practices

9. Raynaud’s Disease Unmet Needs

10. Key Endpoints of Raynaud’s Disease Treatment

11. Raynaud’s Disease Marketed Products

12. Raynaud’s Disease Emerging Drugs and Latest Therapeutic Advances

13. Raynaud’s Disease Seven Major Market Analysis

14. Attribute Analysis

15. Raynaud’s Disease Market Outlook (In US, EU5, and Japan)

16. Raynaud’s Disease Access and Reimbursement Overview

17. KOL Views on the Raynaud’s Disease Market

18. Raynaud’s Disease Market Drivers

19. Raynaud’s Disease Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Learn how the Raynaud’s Disease market will evolve by 2032 @ 



About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.


Other Trending Healthcare Reports by DelveInsight 

Adenosine Deaminase-Severe Combined Immunodeficiency Market

“Adenosine Deaminase-Severe Combined Immunodeficiency Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Adenosine Deaminase-Severe Combined Immunodeficiency market trends in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan). Moreover, it covers the current treatment practices, emerging drugs, market share of individual therapies, treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Adenosine Deaminase-Severe Combined Immunodeficiency market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/